Icon Advisers’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-9,882
Closed -$4.36M 193
2020
Q3
$4.36M Hold
9,882
0.86% 31
2020
Q2
$3.58M Sell
9,882
-1,805
-15% -$605K 0.7% 38
2020
Q1
$3.31M Hold
11,687
0.72% 33
2019
Q4
$3.8M Hold
11,687
0.54% 58
2019
Q3
$3.4M Sell
11,687
-28,951
-71% -$8.29M 0.5% 62
2019
Q2
$11.9M Hold
40,638
1.12% 24
2019
Q1
$11.1M Sell
40,638
-19,708
-33% -$4.9M 1.12% 23
2018
Q4
$13.5M Sell
60,346
-3,348
-5% -$786K 1.42% 13
2018
Q3
$15.5M Sell
63,694
-22,519
-26% -$5.18M 1.32% 16
2018
Q2
$17.9M Buy
86,213
+4,499
+6% +$955K 1.35% 16
2018
Q1
$16.9M Buy
81,714
+6,914
+9% +$1.45M 1.28% 16
2017
Q4
$14.2M Buy
74,800
+27,900
+59% +$5.34M 0.98% 26
2017
Q3
$8.87M Buy
46,900
+3,100
+7% +$561K 0.62% 39
2017
Q2
$7.64M Sell
43,800
-7,600
-15% -$1.28M 0.53% 57
2017
Q1
$7.89M Buy
51,400
+6,200
+14% +$948K 0.54% 55
2016
Q4
$6.38M Buy
+45,200
New +$6.66M 0.43% 75
2015
Q1
Sell
-37,000
Closed -$4.64M 363
2014
Q4
$4.64M Sell
37,000
-4,000
-10% -$486K 0.28% 108
2014
Q3
$4.99M Buy
+41,000
New +$4.99M 0.29% 100

Other funds holding TMO

Icon Advisers's TMO Position: Q4 2020 in Review

Icon Advisers sold out of Thermo Fisher Scientific (TMO) in Q4 2020, closing a stake of 9,882 shares — an estimated $4.36M sold.

Icon Advisers first reported a position in TMO in Q3 2014 and held it in 18 quarters. The position peaked at $17.9M in Q2 2018. 2,030 funds tracked by Wall St. Rank hold TMO as of Q4 2020.

  • Icon Advisers reported no remaining Thermo Fisher Scientific position as of Q4 2020 after selling out during the quarter.
  • Icon Advisers sold 9,882 Thermo Fisher Scientific shares in Q4 2020, an estimated $4.36M.
  • Icon Advisers first reported a position in Thermo Fisher Scientific in Q3 2014 and held it in 18 quarters.
  • Icon Advisers's Thermo Fisher Scientific position peaked at $17.9M in Q2 2018.
  • 2,030 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2020.

Based on Icon Advisers's 13F filing for Q4 2020, filed 2 Feb 2021.